PDF(Pubmed)
Abstract：
The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways. Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype 3 patients with compensated cirrhosis. In an era where additional clinical trial data are not anticipated, clinical guidance should consider experience gained in real-world settings. Although more experience is required for some pangenotypic therapeutic options, on the basis of published real-world data, there is already sufficient evidence to consider a simplified approach for genotype 3 patients with compensated cirrhosis. The coronavirus disease 2019 (COVID-19) pandemic has highlighted the need to minimise the need for complex patient pathways and clinical practice guidelines need to continue to evolve in order to ensure that patient outcomes remain optimised.
摘要：
用于治疗丙型肝炎（HCV）的泛基因型直接作用抗病毒药物的可用性为简化患者途径提供了机会。最近的临床实践指南已经认识到需要简化以确保消除HCV作为公共卫生问题仍然是优先事项。尽管朝着简化的治疗算法迈进，对于基因3型代偿期肝硬化患者的治疗建议仍有一些复杂性.在一个预期不到额外临床试验数据的时代，临床指导应考虑在现实环境中获得的经验.虽然一些泛型治疗选择需要更多的经验，根据公布的真实世界数据，已经有足够的证据考虑对3型代偿期肝硬化患者采用简化方法.2019年冠状病毒病（COVID-19）大流行凸显了将对复杂患者路径的需求降至最低的必要性，临床实践指南需要继续发展，以确保患者预后保持最佳。
